GLP-1 guide
Stopping GLP-1: a clinical decision, not a test of willpower.
Appetite can return. Weight can come back. That is not a personal failure — it is what the evidence would lead you to expect for many people. This guide explains what may change, what the studies show, and what to discuss before you stop.
Plan the exit, not just the stop.
Stopping is easier to navigate when you know what to watch, what to maintain, and when to call. The decision is yours and your prescriber’s — not a verdict on your character.
Quick answer
What happens when you stop.
A short answer, with the uncertainty left in.
For many people, appetite and food noise return, and weight regain is common. In the STEP 1 extension, participants regained about two-thirds of their prior weight loss within a year after stopping semaglutide, and cardiometabolic improvements moved back toward baseline. In SURMOUNT-4, participants who stopped tirzepatide regained weight, while those who continued maintained it.
That does not mean regain is guaranteed, or that stopping is wrong. It means the decision deserves a plan: why you are stopping, how you will monitor, what you will maintain, and what you will do if weight or symptoms change. There is no single label-defined taper schedule for every product; your prescriber decides what is appropriate.
What may change
Four things to watch — without assuming the worst.
These are common patterns, not predictions about you.
Appetite and food noise
The appetite suppression that made meals feel easier may fade. Some people notice food thoughts returning quickly; others notice a gradual shift. This is biology, not a lack of discipline.
Weight trend
Weight may drift upward, stay stable, or continue to change. A weekly trend is more useful than a single reading. Early changes are easier to discuss with your prescriber than late ones.
Cardiometabolic markers
Blood pressure, glucose, and other markers may move back toward where they were before treatment. Follow-up labs and visits are part of the plan, not an afterthought.
GI symptoms and mood
Some people feel better off the medication; others notice changes in digestion, sleep, or mood. Report persistent or severe symptoms rather than guessing.
The evidence
What the studies can — and cannot — tell you.
Two large trials are useful context. Neither predicts your individual outcome.
| Study | What happened after stopping | What it does not mean |
|---|---|---|
| STEP 1 extension (semaglutide) | Participants regained about two-thirds of prior weight loss within a year; cardiometabolic improvements moved back toward baseline. | It does not mean everyone regains the same amount, or that stopping is always the wrong choice. |
| SURMOUNT-4 (tirzepatide) | Participants who stopped regained weight; those who continued maintained it. | It does not mean medication must continue forever for every person. |
These are summaries of trial results, not individualized predictions. Discuss your history, goals, and risks with your prescriber.
Before you stop
Questions worth asking.
Bring these to your prescriber. The answers should shape the plan.
- Why are we considering stopping — cost, side effects, pregnancy, surgery, supply, or preference?
- Should I taper, and if so, how? Is there a schedule for my specific product?
- What should I monitor — weight, appetite, glucose, blood pressure, symptoms?
- How often should we check in after stopping?
- What is the plan if weight regain or symptoms return?
- Can I restart later, and how would that work?
- Do any of my other medications or conditions change the plan?
Keep the habits, not the blame.
- Protein: use a general adult range, not a perfect number.
- Strength: two to three nonconsecutive sessions per week is a common starting point.
- Activity: build regular movement you can sustain.
- Sleep and recovery: they affect appetite and energy.
- Self-monitoring: weight trend, appetite, and symptoms.
- Follow-up: keep the appointments, even when things feel fine.
These habits support maintenance. They are not a guarantee.
Track it
Catch the trend before it becomes a crisis.
A weekly record gives you something concrete to discuss.
- Weight trend, not daily fluctuations.
- Appetite, fullness, and food noise.
- Protein intake and tolerance.
- Strength, activity, and function.
- Sleep, mood, and any symptoms.
A record for the next decision.
The app keeps weight trend, doses, symptoms, nutrition, and notes in one timeline. If you stop or restart, the history stays with you.
Red flags
When to contact your prescriber.
These situations need individual care, not a general guide.
- Rapid weight loss or regain that feels out of control.
- Severe or persistent nausea, vomiting, abdominal pain, or dehydration.
- New or worsening weakness, dizziness, or fainting.
- Pregnancy, planning pregnancy, or breastfeeding.
- Planned surgery or a procedure requiring anesthesia.
- Return of disordered eating thoughts or severe mood changes.
Sources
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension.Diabetes, Obesity and Metabolism. 2022;24(8):1553–1564.doi:10.1111/dom.14725.
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48.doi:10.1001/jama.2023.24945.
- FDA prescribing information for Ozempic, Wegovy, Mounjaro, and Zepbound, viaDailyMed, accessed November 9, 2026.
- World Health Organization,WHO Guidelines on Physical Activity and Sedentary Behaviour(2020).
Last updated: November 9, 2026.
Stopping GLP-1 questions.
What happens when you stop GLP-1?
Do you always gain weight back after stopping?
Should I taper off GLP-1?
How do I maintain weight after stopping?
Can I restart GLP-1 later?
Is stopping a failure?
Is this medical advice?
Keep exploring
Plan the exit
Stopping is a decision. Tracking makes it a plan.
Keep weight trend, appetite, symptoms, and dose history in one private timeline.
- 1M+ installs since 2013
- Current version 4.2
- No account required
- Free on Android